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n recent years, the clinical application of regenerative medicine using stem cells has been heralded as a new approach to the treatment of cerebral infarction. 1 In Japan, various clinical trials on cell-based products are being initiated in patients with the disease. 2, 3 However, the full-scale clinical use of such products remains a major challenge. Unsolved questions include how nonclinical studies should be conducted and what type of designs should be used in clinical trials. Similar questions have remained in the United States. Researchers in the academia, industry leaders, and regulatory representatives organized the Stem Cell Therapeutics as an Emerging Paradigm in Stroke (STEPS) program, which proposed basic approaches to quality assurance, nonclinical studies, and clinical trials in the development of cellbased products for the treatment of cerebral infarction. [4] [5] [6] In Japan, the government has published guidelines for ensuring the quality and safety of individual cell-based products that are used as raw materials. However, no specific guidelines have been established for cell-based products for the treatment of cerebral infarction. Although the STEPS has proposed helpful basic approaches to the development of such regenerative medicine products, guidelines are needed that are based on Japanese regulations, taking into consideration the clinical setting of cerebral infarction treatment in the country. 7 Such guidelines would be useful to facilitate appropriate development of the products. For these reasons, we prepared the Guidelines on Development of Cell-based Products for the Treatment of Cerebral Infarction. The guidelines comprised consensus about quality assurance, nonclinical studies, cell delivery methods, and clinical trials on products that were discussed in relevant individual working groups, while considering disease-specific issues and the existing Japanese guidelines on ensuring quality and safety of cell-based products for individual cell types.
The original guidelines in Japanese language were framed by Working Group for Guidelines on Development of Subsequently, the guidelines were translated into English by the working group. The English version of the guidelines was published under the responsibilities of the working group. The English guidelines are included as an appendix in the onlineonly Data Supplement to the present article. In this article, we introduce our new guidelines on the development of cellbased products for the treatment of cerebral infarction and provide updated information on the regulations for regenerative medicine in Japan.
Regulatory Framework for Regenerative Medicine in Japan
We provide a description of the new regulations and approval process for regenerative medicine in Japan. 9 The previous health research regulations in Japan are outlined in Figure 1 . Historically, when intervention studies intended for the application of marketing authorization of drugs and medical devices were designed, these studies, regardless of whether they were classified as sponsor-investigator or company-sponsor clinical trials, were regulated under Pharmaceutical Affairs Law by the Pharmaceuticals and Medical Devices Agency (PMDA), which is the regulatory agency in Japan, and Pharmaceutical and Safety Environmental Health Bureau, MHLW. On the other hand, sponsor-investigator health research for academic purposes other than marketing authorization were covered by Health Policy Bureau, MHLW. These previous health research regulations had 2 serious flaws in regard to regenerative medicine. One issue was that no specific category included any cell products in Pharmaceutical Affairs Law; the second was that no act regulated any therapies using cell-based products, which were not covered by health insurance.
When more detailed information is required about the new regulatory framework for regenerative medicine in Japan, see the cited papers in which the highlights of the new regulations were introduced.
New Acts Regarding the Regulation of Stem Cell Therapies
In fall 2014, 2 acts related to the regulation of stem cell therapies were launched ( Figure 2) . 10, 11 One was the Act on the Safety of Regenerative Medicine (Safety Act); the other was the Act on Pharmaceuticals and Medical Devices (PMD Act), representing a revision of Pharmaceutical Affairs Law. The Safety Act covers all medical technologies that use processed cells and whose safety and efficacy have not yet been established. It may be similar to the researcher-initiated Investigational New Drug Application system. On the other hand, the PMD Act covers the production and marketing of cell-based products produced by firms. It is equivalent to the company-driven Investigational New Drug and product approval system. When Pharmaceutical Affairs Law was revised to form the PMD Act, a definition of and independent chapter on Regenerative Medical Products were added. Of note, a conditional/term-limited approval system was also introduced.
The Safety Act
The Safety Act obligates hospitals and clinics in Japan to submit plans for the provision of regenerative medicine to MHLW. The certified special committee or certified committee for regenerative medicine, which is certified on the basis of the Act by MHLW, reviews the plans for provision of regenerative medicine in advance. The Act enables hospitals and clinics to commission cell processing to licensed enterprises. Moreover, it obligates cell processing centers in hospitals and clinics to notify MHLW or those in firms to obtain a manufacturing license. 9 Under the Safety Act, regenerative medical technologies are divided into 3 classes depending on their potential risk to human health (Table 1) . Under Class I, the representative objects are not only induced pluripotent stem cells (iPSCs) and embryonic stem cells, but gene-introduced, xenogeneic, and allogeneic cells. For example, transplantation of retinal pigment epithelium cells derived from autologous iPSCs was conducted under Class I of the Act. 12 Under Class II, the representative object is autologous somatic stem cells, and under Class III, it is cancer immunotherapy using autologous somatic cells. 
The PMD Act
The PMD Act, a new regulatory framework, defines regenerative medical products as a new category to ensure timely provision of safe regenerative medicines. Moreover, after safety has been confirmed and results predict the likely efficacy of a regenerative medical product, the product is given conditional/term-limited marketing authorization to enable timely provision of products to patients, as part of an expedited approval system for regenerative medical products. Specifically, if clinical trials confirm safety and are likely to predict efficacy in phase 2, conditional/term-limited authorization is granted to the product as part of the new scheme for regenerative medical products ( Figure 3 ). Further confirmation of efficacy and safety are subsequently needed during the marketing of the product. Within 7 years, reapplications for marketing authorizations must be submitted. As an example, in 2015, HeartSheet (Terumo Co, Tokyo, Japan) was approved under the PMD Act. 13 HeartSheet is an autologous skeletal myoblast sheet used to treat severe heart failure because of ischemic heart disease. A singlearm, open-label, phase 2 study was conducted before the product's approval. The term limit is 5 years, and reapplications for marketing authorization must be submitted after this date.
The Strategy of SAKIGAKE
We also introduce the Strategy of SAKIGAKE, which means fast-track in Japanese.
14 The MHLW announced the Strategy of SAKIGAKE in 2015 to accelerate the development of innovative medical products. The Strategy of SAKIGAKE covers basic research, clinical trials, approval reviews, safety measures, insurance coverage, improvement of infrastructure and the environment for corporate activities, and global expansion. In collaboration, MHLW and PMDA will work toward implementation of the strategy. The Strategy of SAKIGAKE has already been designated to 3 cell-based products for central nervous system diseases: autologous mesenchymal stem cells for spinal cord injury (STR01, Nipro Co, Osaka, Japan), 15 allogeneic iPSCs-derived neuronal precursor cells for Parkinson's disease (Sumitomo Dainippon Pharma Co, Ltd, Osaka, Japan), 16 and adult bone marrow-derived allogeneic stem cell for acute ischemic stroke (HLCM051, Healios K. K., Tokyo, Japan).
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New Guidelines on the Development of Cell-Based Products for the Treatment of Cerebral Infarction
In this chapter of the present article, we first describe previously conducted as well as ongoing clinical trials in Japan that investigated cell therapies for stroke. These trials were planned before publication of the new Japanese guidelines, Guidelines on Development of Cell-Based Products for the Treatment of Cerebral Infarction. Next, the preparation, scope, and objectives of the guidelines are introduced. Finally, summaries of the guidelines' chapters, Quality, Nonclinical Studies, Cell Delivery Methods, and Clinical Studies, are provided. 
Previous and Ongoing Clinical Trials on Cell Therapies for Stroke in Japan
In Japan, autologous bone marrow-derived cells were historically the dominant cell source used in clinical trials on stroke. Honmou et al 2 reported a phase 1/2 trial using autologous mesenchymal stem cells (STR01) in 2011. Twelve patients with cerebral infarction received intravenous cell infusion in the acute phase. Results showed that there was improvement in neurological symptoms in all patients, and adverse cell-related, serological, or imaging-defined effects were not observed. The authors concluded that intravenous administration of autologous mesenchymal stem cells appeared to be feasible and safe and that it merited further study as a therapy to improve functional recovery. The group has ongoing phase 3 trials (registration ID: JMA-IIA00117).
Around the same time, Taguchi et al 3 conducted phase 1/2 trials with autologous bone marrow mononuclear cells. Subjects were 12 patients who had cardiogenic embolism in the acute phase. Bone marrow mononuclear cells were administered intravenously 7 to 10 days postischemia. The authors reported lack of cell-related adverse effects. The group is now preparing investigator-initiated phase 3 clinical trials.
Some clinical trials using allogeneic cell products have also recently begun in Japan. Hess et al 17 reported a study with MultiStem stem cells (Athersys Inc., Cleveland, OH). Thirtythree hospitals in the United States and the United Kingdom participated in this double-blind, randomized, placebo-controlled, phase 2 safety and efficacy trial. The cell source was allogeneic bone marrow-derived cells. A phase 2/3 efficacy and safety trial in patients with ischemic stroke has also begun in Japan (HLCM051, registration ID: NCT02961504).
Steinberg et al 18 reported a phase 1/2A study with SB623 cells (SanBio Inc, Mountain View, CA) for chronic ischemic stroke. The study involved 2-center, open-label, safety, and dose escalation feasibility trials conducted in the United States. The cell source was genetically modified bone marrow cells.
In Japan, international clinical trials with SB623 for traumatic brain injury have begun (registration ID: NCT02416492), and clinical trials for chronic ischemic stroke are planned.
Recently, Houkin et al began a phase 1 clinical trial for acute ischemic stroke patients (registration ID: UMIN000026130). 19 In this study, autologous bone marrow stromal cells are cultured with human platelet lysate as a substitute for fetal calf serum, 20, 21 and the cell product (HUNS001-01) is stereotactically transplanted around the infarct. The study protocol was essentially composed under the new guidelines because the plan for this study and the preparation of the guidelines proceeded under the Initiative for Accelerating Regulatory Science in Innovative Drug, Medical Device, and Regenerative Medicine, which is described in the next chapter, simultaneously.
New Guidelines Encourage the Development of Cell Therapies for Stroke in Japan
Compared with the success of basic research on stem cells, such as the establishment of iPSC, 22 the number of clinical trials examining cell products are lower in Japan. To encourage the translation of basic scientific research into clinical practice, in 2012, MHLW launched the Initiative for Accelerating Regulatory Science in Innovative Drug, Medical Device, and Regenerative Medicine. The project aimed to promote the establishment of various guidelines for the development of new drugs, medical devices, and regenerative medicines; it also promoted human resource development via personal exchange between research institutes and regulatory agencies, such as PMDA (Figure 4) . 23 As one of such schemes, the collaboration between Hokkaido University and PMDA began development of the autologous mesenchymal stem cell therapy for stroke, as mentioned above. The collaborative effort also organized Working Group for Guidelines on Development of Cell-Based Products for the Treatment of Cerebral Infarction, which aimed to establish new guidelines for cell therapies for stroke, in November 2013. The members consisted of neurosurgeons, neurologists, a neuroradiologist, a neurorehabilitation physician, basic and regulatory scientists, and PMDA reviewers. It was important for Japan to take an original stance because of domestic regulations for regenerative medicine, although the STEPS program was used as a reference. It was noteworthy that not only the researchers but also PMDA were able to use the guidelines to review the cell products to treat stroke before the clinical trials started.
Scope and Objectives of the Guidelines
The new Japanese guidelines focused on cerebral infarction, on which many studies for possible clinical application of cell therapy have been conducted. One-size-fits-all guidelines will not enable appropriate research and development of individual cell-based products because cell therapies and cell types greatly vary among different neurological diseases.
The guidelines apply principally to products derived from autologous or allogenic human somatic stem cells. For the development of products derived from transgenic cells, embryonic stem cells, and iPSCs, the guidelines described only general considerations that are common to various types of cell-based products. In addition, the guidelines did not cover noncellular therapeutic products for tissue regeneration or other purposes.
The guidelines described specific approaches to developing cell-based products for the treatment of cerebral infarction on the basis of the existing Japanese guidelines. [24] [25] [26] [27] Other useful references included the Technical Guidance on Quality, Nonclinical Studies, and Clinical Trials of Regenerative Medicine Products. 28 It described the regulatory authority's perspectives on the development of cell-based products.
The new Japanese guidelines were designed to serve as a reference for developers who will conduct any clinical trial on cell-based products for the treatment of cerebral infarction in Japan. It should be noted that the guidelines aimed to facilitate, rather than restrict, the course of product development. Developers should assess the needs of each test on the basis of properties of individual products for development. The guidelines should be regularly reviewed and updated as necessary because regenerative medicine has been advancing rapidly. The contents of the guidelines are shown in Table 2 . More detailed information can be found in the relevant part of the guidelines. The following are described as summary and basic principles of the new guidelines for quality assurance, nonclinical studies, cell delivery methods, and clinical trials.
Quality
To ensure the quality of regenerative medicine products for the treatment of cerebral infarction, the quality of the product (1) should be understood on the basis of its mechanism of action and other properties; manufacturing processes should also be understood; and appropriate quality control procedures should be established in consideration of possible risks to quality (2) . Similar to the general principles of ensuring the quality of other regenerative medicine products, appropriate procedures should be performed for the manufacturing process and the quality maintenance of product materials; the quality of the final products should be controlled with in-process control test. Because information on quality test results of the final products is limited and the number of specimens used for quality test is restricted, a comprehensive evaluation of quality control strategy should be established for each product with an assessment of the conditions of in-process control test and manufacturing control. Although development of cell-based products derived from human somatic stem cells for the treatment of cerebral infarction was initiated earlier than that from other cell types, the existing Japanese guidelines should be referred to, depending on the cell types used as materials. When investigational products, instead of marketed products, are used in clinical trials or in other developmental stages, experience of manufacturing might be less; this could result in insufficient assessment of the efficacy and safety of the investigational products. However, measures that are necessary, appropriate, and feasible for the developmental stages and properties of the investigational product should be taken to ensure quality. 1. Quality properties or characteristics of cells necessary to exhibit the desired actions of the product 2. Quality-related factors that may affect the safety and efficacy of the product
Nonclinical Studies
In the chapter of the guidelines on nonclinical studies, 3 important contents are examined: studies supporting potency or efficacy, in vivo pharmacokinetic studies, and studies suggesting nonclinical safety (toxicity). In the section discussing studies that support potency or efficacy of the product, details of the animal species and models of cerebral infarction, study design, outcome measures, and mechanisms of action are described. In particular, the use of large animals and the difference in treatment protocols between nonclinical studies and clinical trials are discussed. Next, the issue of in vivo pharmacokinetics, which consists of the distribution and viability of administered cells and in vivo imaging, is described. This section discusses issues particular to cell therapy, and the discussion is separated according to the cell delivery route. Finally, nonclinical safety, which is also known as toxicity, is described. In this section, details on general toxicity, tumorigenicity, and safety of pharmacology studies are explained, as well as the safety of noncellular components and impurities. In this section, some regulations to be referenced are also introduced.
Cell Delivery Methods
Cell therapy for central nervous system diseases can use various cell delivery routes, such as intravenous, intra-arterial, and intracerebral, depending on the cell-based products, which may need specific devices for cell delivery. In nonclinical studies, the possibility of using the treatment regimens in humans should be presumed. These studies should use animal species that allow evaluation of safety and efficacy of such regimens. In clinical trials, treatment regimens should be based on those tested in nonclinical studies and should be evaluated for safety and efficacy in humans. Assessment of treatment regimens requires selection of the absolute number of cells to be administered, number of cells per unit volume or cell density, and total volume of the product administered.
The maximum tolerated dose should be explored in nonclinical studies. For risk assessment of treatment regimens, possible risks should be divided into 2 categories: risks related to products and risks related to cell delivery techniques. If any treatment regimen with little human clinical experience is used, information on the clinical experience with the regimen and with other similar regimens should be collected.
The safety of such regimen should be evaluated comprehensively.
Clinical Trials
The goal of treatment of cerebral infarction is to resolve the resulting neurological disorder. The basic principles of treatment using cell-based products are the same as those using pharmaceutical products or medical devices, except for the absence of any sufficiently established principles regarding the development phases of cell-based products. For the clinical development of cell-based products, the objectives and roles of each clinical trial in the entire development process should be determined based on the properties of each investigational product and the established basic principles of the development phases of pharmaceutical products and medical devices. The efficacy, safety, and tolerability of cell-based investigational products should be evaluated in early-phase clinical trials on patient populations. The therapeutic strategies for cerebral infarction typically vary with the disease stage (ie, hyperacute, acute, subacute, and chronic) and should be considered. Some strategies aim to improve blood flow in the ischemic areas; others intend to preserve neuronal structure and function before an ischemic disorder develops; and some aim to resolve an established neurological dysfunction. Depending on the selected strategy for the investigational product, the appropriate target population, treatment regimen, and efficacy end points should be defined for each clinical trial.
In the development of allogenic cell-based products, clinical trial designs could be similar to those used for pharmaceutical products and medical devices. In the development of autologous cell-based products, clinical trial designs have specific considerations related to tissue collection and manufacturing periods. The objectives and roles of each clinical trial in the entire development process should be determined according to the properties of the investigational product derived from autologous cells. Table 2 
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The existing Japanese guidelines and notifications on clinical trials of cell-based products are available as references.
29-31
Difference With STEPS
The new Japanese guidelines were also designed for reviewers in PMDA to assess the application about the developmental cell-based products for stroke. Although the STEPS has proposed helpful basic approaches in the development of such products, developers require helpful information based on Japanese regulations, taking into consideration the clinical setting of cerebral infarction treatment in the country. The Japanese regulatory authorities have published some guidelines for ensuring the quality and safety of individual cellbased products. The new guidelines serve as a reference for developers to conduct any clinical trial on cell-based products for the treatment of cerebral infarction in Japan.
Regarding the cell delivery methods, for example, we focus on the difference between the new Japanese guidelines and the STEPS. STEPS I, 4 which was published in 2009, stated that the choice of delivery method will depend on the type of cell, location of stroke, the patient's comorbidities and prognosis, and intended strategy to promote recovery. The concept for the cell delivery methods was followed in STEPS II and III, 5, 6 and we almost agreed with it from a researcher's view. Because we placed emphasis on the discretion of the individual developers and protection of human subjects, it may seem to the readers that only one aspect of safety was discussed in the chapter Cell Delivery Methods. However, we were sure that it was useful information for developers and reviewers to discuss the risk of the regimens based on the cell delivery route.
Although the new guidelines comprised consensus regarding quality assurance, nonclinical studies, cell delivery methods, and clinical trials on products, they do not aim to restrict the course of product development. Therefore, they provide checkpoints about safety concerns but not specific information regarding controversial issues, for example, what models and species are preferred for cell therapy assessment in the preclinical study or if large animal models (eg, primates) are recommended. On the other hand, regarding the controversial issues, STEPS II stated that evaluation of a cell-based approach was important in multiple focal ischemic stroke or intracerebral hemorrhage models using appropriate histological and behavioral tests and that large animal models may be helpful for specific situations in which they permit testing of specific neuroanatomical structures (white matter), specific types of imaging, or delivery options. 5 Moreover, it stated that animal models should be exploited to examine the effects of age (young versus old), sex, and comorbidities (hypertensive, diabetic, etc) on the therapy being investigated. 5 Although we considered whether each statement should be recommended in our guidelines, we decided to leave the issues to the discretion of the developers by consensus.
Our new guidelines, on the other hand, provided much more information about the quality assurance on cell-based products than the STEPS because the quality of cell-based products was linked closely to the protection of human subjects, on which we placed emphasis. In fact, our guidelines provided the contents about materials management, manufacturing methods, and quality control of the final products, which included identification, cell purity, process-related impurity, efficacy/potency, and sterility/mycoplasma tests. Although these issues were discussed based on Japanese regulations, we are sure that the basic principles will be helpful for developers conducting any clinical trial on cell-based products in other countries to ensure the quality of cell-based products.
Conclusions
In this article, we introduced our new guidelines on the development of cell-based products for the treatment of cerebral infarction. As background, we provided updated information on the Japanese regulations for regenerative medicine and gave an overview of previous and ongoing clinical trials examining cell therapies for stroke in Japan. We think that the new guidelines will encourage the development of cell therapies for stroke in Japan.
